YIFAN PHARMACEUTICAL(SZ:002019) Xin Lang Cai Jing·2026-01-07 08:58Core Viewpoint - Yifan Pharmaceutical's wholly-owned subsidiary has received a production registration acceptance notice for Yihuang Decoction Granules, marking a significant step in the company's product development as it is the first classic prescription variety registered by the company [1] Company Summary - Yifan Pharmaceutical (002019.SZ) announced that its subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the production registration of Yihuang Decoction Granules on January 6, 2026 [1] - Yihuang Decoction Granules are indicated for kidney strengthening and dampness clearing, representing a new product offering in the company's portfolio [1] - As of the report date, there are no other products in the domestic market derived from the same prescription, with only one other company currently undergoing the application review process [1] Industry Summary - The acceptance of the registration application indicates a potential market opportunity for Yihuang Decoction Granules, as it is a unique product with no direct competitors in the domestic market [1] - The drug will proceed to the drug review center for evaluation and approval following the acceptance by the regulatory authority, highlighting the regulatory pathway for new pharmaceutical products in the industry [1]